Related Experiment Video
Updated: Nov 3, 2025
Author Spotlight: Integrating 2D-HPLC-MS and Molecular Networking in Natural Medicine Analysis
Published on: December 8, 2023
Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS
Wen-Long Wei1, Shi-Fei Wu1, Hao-Jv Li1
1Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Insights
Huashi Baidu prescription (HSBDF) contains 217 chemical constituents and may fight COVID-19 by reducing inflammation. This study characterized HSBDF
Area of Science:
- Traditional Chinese Medicine
- Pharmacology
- Immunology
Background:
- Huashi Baidu prescription (HSBDF) is a traditional Chinese medicine used for treating severe COVID-19 symptoms.
- Its efficacy may be linked to anti-inflammatory properties, but its chemical profile and specific mechanisms are not fully understood.
Purpose of the Study:
- To characterize the chemical constituents of HSBDF.
- To investigate the in vitro anti-inflammatory effects of HSBDF on lipopolysaccharide (LPS)-stimulated RAW264.7 cells.
Main Methods:
- UPLC-Q-TOF/MS was used to identify chemical constituents in HSBDF.
- Enzyme-linked immunosorbent assays (ELISA) were employed to measure pro-inflammatory cytokines (IL-6 and TNF-α) in LPS-stimulated RAW264.7 cells treated with HSBDF.
Main Results:
- A total of 217 chemical constituents were tentatively identified in HSBDF.
- HSBDF significantly reduced the expression levels of IL-6 and TNF-α in the cell model.
- These findings suggest HSBDF possesses anti-inflammatory activity.
Conclusions:
- HSBDF contains a complex mixture of chemical compounds.
- The anti-inflammatory effects of HSBDF may contribute to its therapeutic potential against COVID-19 by modulating cytokine production.
Abstract:
Huashi Baidu prescription (HSBDF), recommended in the Guideline for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Pneumonia (On Trials, the Seventh Edition), was clinically used to treat severe corona virus disease 2019 (COVID-19) with cough, blood-stained sputum, inhibited defecation, red tongue etc. symptoms. This study was aimed to elucidate and profile the knowledge on its chemical constituents and the potential anti-inflammatory effect in vitro. In the study, the chemical constituents in extract of HSBDF were characterized by UPLC-Q-TOF/MS in both negative and positive modes, and the pro-inflammatory cytokines were measured by enzyme-linked immunosorbent assays (ELISA) to determine the effects of HSBDF in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. The results showed that a total of 217 chemical constituents were tentativedly characterized in HSBDF. Moreover, HSBDF could alleviate the expression levels of IL-6 and TNF-α in the cell models, indicating that the antiviral effects of HSBDF might be associated with regulation of the inflammatory cytokines production in RAW264.7 cells. We hope that the results could be served as the basic data for further study of HSBDF on anti-COVID-19 effect.
More Related Videos
07:16Preparation of Gynura bicolor DC samples for High-Resolution Tandem Mass Spectrometry
Published on: February 2, 2024
09:16Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method
Published on: May 12, 2023